Posts Tagged ‘black box warning’

Prozac is now a defense for murder, writes Australian Member of Parliament Martin Whitely

Wednesday, December 21st, 2011

For the first time in criminal history, a murder was attributed to an anti-depressant drug. (Photo Credit -The Daily Telegraph)

Perth Now – December 21, 2011

FIRST it was ADHD drugs, then organ donation, now WA Labor MP Martin Whitely is hoping to get some action on the fatal risks of antidepressant drugs, such as Prozac, to children.

Anti-depressant manufacturers warn that products such as Prozac should not be given to children, because of the potentially tragic consequences, but they are prescribed every day to Australian kids.

Some anti-depressants, prescribed to help lift people out of a depressive state, actually have the opposite effect and make things worse.

This is what happened, with fatal results, in the case of a 16-year-old boy in Canada who stabbed a friend to death.

For the first time in criminal history, a murder was attributed to an anti-depressant drug.

In the finding, handed down on the 16th of September 2011, a Canadian Judge said a 16-year-old boy, who stabbed his brother’s friend in the stomach, would not have committed the offence had he not been treated with the drug Prozac (a brand of Fluoxetine).

The judge accepted the evidence of psychiatrist, Dr Peter Breggin, who told the court the boy’s symptoms were consistent with a Prozac-Induced Mood Disorder with Manic Features.

In delivering his decision the judge stated, “his basic normalcy now further confirms he no longer poses a risk of violence to anyone and that his mental deterioration and resulting violence would not have taken place without exposure to Prozac”.

The boy, who had no history of violence, had been taking Prozac for three months, during which his parents observed a marked deterioration in his behaviour and mood, which included acts of violence and self-harm where previously no such signs existed.

His alarmed parents returned to his doctor for advice, but instead of taking him off Prozac or reducing his dosage, his doctor increased the dose, obviously believing more of what appeared to be causing these dangerous behaviours, would solve the problem.

Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) and is approved for use in Australia for the treatment of depression, obsessive compulsive disorder and premenstrual dysphoric disorder.

However, it is routinely prescribed ‘off label’ for a range of other conditions including panic and eating disorders.

Australian Government Department of Health and Ageing figures revealed that in the 2008 financial year, 110,848 Australians received Fluoxetine scripts that were subsidised via the Pharmaceutical Benefits Scheme.

Concerns about possible aggression and manic side effects of Prozac were first raised in Australia in the New South Wales parliament in 1995, just five years after the release of the drug in Australia.

Since 2007, the US Food and Drug Administration has labelled SSRI antidepressants including Prozac with the highest possible ‘black box’ warning stating:

“All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases. The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have been reported in adult and pediatric patients being treated with antidepressants for major depressive disorder as well as for other indications, both psychiatric and non-psychiatric.”

The US Black Box warning was followed by similar warnings in Australia. The evidence that led to these warnings came from, ‘pooled analyses of short-term placebo-controlled trials of anti-depressant drugs (SSRIs and others)’ which ‘showed that these drugs increase the risk of suicidal thinking and behavior (suicidality) in children, adolescents [by 100%], and young adults ages 18-24 (by 50 per cent) with major depressive disorder (MDD) and other psychiatric disorders.’ The fact that SSRI antidepressants like Prozac are supposed to manage severe depression in young people but increase the risk of suicidality poses obvious questions.

Over a 10 year period, up until 30 June 2011, more than 40 adverse events of self-harm and violence, including suicides, homicides and suicidal or homicidal ideation, for Fluoxetine were reported to the Australian Therapeutic Drugs Administration (examples are listed below).

Hundreds of reports were recorded by the TGA for other antidepressants however, it is impossible to know the true number of actual events, as the voluntary nature of the reporting system means only a fraction of actual incidents gets reported.

Despite the fact that the manufacturers advise that Prozac and other SSRI antidepressants are ‘not recommended for use in children and adolescents under 18 years of age’ they are frequently prescribed ‘off label’ to even very young children.

Data provided by the Commonwealth Department of Health revealed that in the 2007-8 financial year 3,752 Australian children 15-years-old or younger (863 were 10 or younger, 117 were six or younger) were prescribed Pharmaceutical Benefits Scheme-funded Fluoxetine.

Furthermore all the expense and risks of adverse side effects may be for little or no benefit. The efficacy of antidepressants are being questioned – with some high profile, mainstream critics, arguing that placebos are just as effective and much safer in treating moderate depression.

One such critic, Marcia Angell, MD, Senior Lecturer on Social Medicine at Harvard Medical School and former Editor-in-Chief of The New England Journal of Medicine, contends; ‘that clinical trials have failed to find antidepressants effective at all in mild to moderate depression; that many psychiatric drugs have devastating adverse effects, especially in children and when used long-term; and that despite the risks and uncertain benefits, use of psychiatric drugs is soaring and the heavy reliance on drugs diverts resources better spent on improving treatment’.

In summary, taxpayers are subsidising the ‘off label’ use by children and adolescents of antidepressants, with questionable efficacy, that double their risk of suicidality. This invites some obvious questions: Is this the best way to spend our taxes? And more importantly, is this the best way to help troubled young people?

* A sample from the Adverse Drug Reactions Committee (ADRAC) adverse event reports for Fluoxetine Hydrochloride:

  • A 54 year old woman attempted suicide. She was also suffering from mania and a confusional state.
  • A 36 year old woman “attempted suicide”.
  • A 36 year old woman was admitted to intensive care in a coma following a suicide attempt.
  • A 51 year old woman “had sudden urge to murder someone”.
  • A 37 year old woman was admitted to a psychiatric hospital suffering from “suicidal ideation, nausea, trembling, feelings of despair, anxiety, paranoia and fear”.
  • A 16 year old boy suffering from agitation and auditory hallucinations heard voices “telling him to kill his mother, father, sister and himself”.
  • A 45 year old man “became obsessively suicidal and cut his throat” 3/7 days after Prozac was stopped.
  • A 17 year old girl “became manic half an hour after commencing antidepressant.”
  • A 40 year old patient “experienced trembling, cramps, heard voices and had suicidal ideation.”
  • A patient of unrecorded gender and age experienced “homicidal and suicidal ideation.”
  • A patient of unrecorded gender and age attempted suicide after experiencing suicidal ideation.
  • A 44 year old patient “experienced akathisia, suicidal ideation and suicide attempt.”
  • A patient of unrecorded gender and age experienced “suicidal violence” and “aggression.”
  • A patient of unrecorded gender and age experienced “suicidal ideation.”
  • A patient of unrecorded gender and age experienced “suicidal ideation and “suicide attempt.”
  • A 50 year old patient experienced “suicidal ideation, suicide attempt and akathisia.”
  • A 37 year old patient attempted suicide.
  • A patient of unrecorded gender and age experienced “suicidal ideation and suicide attempt.”
  • A patient of unrecorded gender and age made a suicide attempt and was violent.
  • A 16 year old girl “attempted to hang herself with television cord from curtain rail in hospital bedroom. Nurse said she found her at the last moment.”
  • A 16year old girl “ingested 40 Panadol tablets. Also frequent self-harming.”
  • A 16 year old girl “attempted suicide by ingestion of 80 Panadol, 20 Panadeine, 7 Olanzapine.”
  • A 29 year old patient “developed acute suicidal akathisia” and made a suicide attempt.
  • A 73 year old patient “experienced homicidal ideation and made a suicide attempt.”
  • A 60 year old woman “experienced suicidal ideation, suicide attempt and homicidal ideation – she attempted to kill her parents.”
  • A 69 year old patient “experienced suicidal ideation and was very anxious.”
  • A 16 year old girl attempted to “strangle herself with and IPod cord in the bathroom of the hospital. Agitation. She ran around crying and banging her fists of the walls and windows begging to be let out. … it lasted about 10 minutes before I could settle her.”
  • A patient of unrecorded gender and age “took a fistful of sleeping pills.”
  • A 35 year old patient “murdered his wife whilst on Prozac. He had also experienced suicidal thoughts.”
  • A female patient of unrecorded age “became seriously depressed, complained of headaches, and clenching jaw, was unable to sleep and started to self-harm. She began to have suicidal thoughts, was hyperventilating, agoraphobic, had five suicide attempts, was confused, tearful, phobic, aggressive, experienced akathisia and suspected serotonin syndrome. She experienced weird dreams, was impulsive, light headed, had numbness and tingling limbs and committed suicide by hanging on 11 September 2000 on the second attempt.”
  • A 50 year old woman “became more depressed whilst taking Prozac. She wanted to throw herself off a train or bus, had difficulty sleeping, was pacing and restless, had voice hallucinations, would look in the mirror and see a different person, had murderous thoughts, stiff legs, was hot a lot, felt she was in a delirium, could not concentrate, was angry, had numbness in her hands and pins and needles a lot in her body.”
  • A 19 year old male “had thoughts about killing himself which made him violent, tried to hit someone else, tried to hit a security guard with feelings of killing and tried to do physical damage. Tried to hurt himself and had thoughts of hurting other people. He was walking faster than normal. Experienced aggression, insomnia and was feeling high on Prozac. Also felt anxious and put on more than 20kg.”
  • A male of unreported age “experienced severe depression, cognitive impairment and was acutely suicidal.”
  • A 16 year old girl was “cutting herself, throwing herself against the walls while an inpatient”. She “intentionally overdosed on Fluroxetine” and “developed severe levels of aggression and violence.”
  • A 14 year old boy experienced “suicidal ideation.”
  • A female of unreported age “experienced suicidal ideation”.
  • A 16 year old girl experienced “excessive bleeding, psychosis, high blood pressure, severe diarrhea, sweating, tremors, violent, aggressive and suicidal behavior, serotonin syndrome.”
  • A 14 year old male experienced “severely increased suicidal ideation in two days with high level of intent and plan to jump in front of train. Previously no suicidal ideation and settled spontaneously within four days of ceasing Fluoxetine”.
  • A female patient experienced a “sudden and marked increase in hostility and verbal abuse of others and describes intrusive suicidal ideation. Seems agitated and restless”.
  • A 32 year old woman experienced “audio hallucinations, bright and blurred vision, made everything sound louder, constipation, increased suicidal thoughts and increased anxiety”

http://www.perthnow.com.au/news/western-australia/prozac-is-now-a-defence-for-murder/story-e6frg13u-1226227796937

Note from CCHR International:  CCHR is the only organization to have decrypted the US FDAs Medwatch reports on adverse reactions to psychiatric drugs and compiled them in an easy to search database.    This database is provided here http://www.cchrint.org/psychdrugdangers/medwatch_psych_drug_adverse_reactions.php

CCHR has also compiled all international drug warnings and studies on psychiatric drugs here http://www.cchrint.org/psychdrugdangers/drug_warnings.php

 

« Return to news items


Share

Cause for alarm: Antipsychotic drugs for nursing home patients

Tuesday, May 31st, 2011

CNN
By Daniel R. Levinson, Special to CNN
May 31, 2011

Daniel Levinson, inspector general for the OIG in the Department of Health and Human Services.

When a loved one moves into a nursing home, the support of family and friends is particularly important. This is especially true when the nursing home patient has dementia and can’t adequately advocate on his or her own behalf.

A newly released report from my office — the Office of the Inspector General for the Department of Health and Human Services — makes clear just how crucial it is for families to monitor and ask questions about medications that such patients receive. The report found that too often, elderly residents are prescribed antipsychotic drugs in ways that violate government standards for unnecessary drug use.

Frequently, they are prescribed in ways that don’t qualify as medically accepted for Medicare coverage. In addition, the drugs were predominately prescribed for uses that are not approved by the Food and Drug Administration.

But the most potentially troubling finding of the study is this: Researchers found that 88% of the time, these drugs were prescribed for elderly people with dementia.

This is precisely the population that faces an increased risk of death when using this class of drugs, according to the FDA. That’s why the agency puts its strongest safety warning, called a “black box warning” on these antipsychotic drugs, cautioning about the risk of death when taken by elderly people with dementia.

The report didn’t investigate why patients with dementia are prescribed antipsychotic drugs so often. But a series of lawsuits and settlements that my office helped bring about suggests that many pharmaceutical companies have improperly promoted these drugs to doctors and nursing homes for many years.

Another view: In defense of antipsychotics for dementia

The study began a few years ago, when a member of Congress questioned how many nursing home residents received a class of antipsychotic drugs introduced in the 1990s, among them risperidone and olanzapine. These drugs are known as “atypical” or “second generation” antipsychotics. They replaced the antipsychotic drugs introduced in the 1950s and 1960s to treat schizophrenia — and, incidentially, are far costlier.

The report found about 305,000 nursing home residents (about 14%) had Medicare claims for atypical antipsychotic drugs. Of these, about one in five residents was prescribed these antipsychotics in a way that violated government standards for their use. For example, residents were on a drug for too long, or at too high a dose.

Another finding: A little more than half the antipsychotic drug claims for which Medicare paid should not have been covered. Why? The claimed drugs were not used for medically accepted reasons or there were no records the drugs were actually provided.

To be clear: Most physicians and nursing homes dispense antipsychotic drugs with the best interests of patients in mind. Physicians can use their medical judgment to prescribe drugs for uses unapproved by the FDA, and also to patients for whom the boxed warning applies. Ideally, however, doctors who prescribe in such ways first determine that the benefits outweigh the risks.

Yet it remains a concern that so many elderly nursing home residents with dementia are prescribed antipsychotics. And, unfortunately, examples abound of companies’ improper promotion of these drugs.

Government investigations of Bristol-Myers Squibb, AstraZeneca and Pfizer found that they improperly promoted their antipsychotic drugs for unapproved uses.

Federal prosecution is pending against Johnson & Johnson for allegedly paying millions of dollars in kickbacks to induce Omnicare, the nation’s largest long-term care pharmacy, to recommend the use of Risperdal in treating nursing home patients, many of whom had dementia.

And Eli Lilly pleaded guilty to criminal charges associated with illegally marketing its drug Zyprexa, including to doctors who treat elderly nursing home patients.

Pharmaceutical companies have paid billions to resolve civil and criminal liabilities under federal health and safety laws. But money can’t adequately compensate for corporate campaigns that could put vulnerable, elderly patients at risk.

How do we solve this problem? There’s plenty to do.

Family members of nursing home residents must learn about their loved ones’ medications, the reasons for their use, proper dosages and possible side effects.

Nursing homes and pharmacies that serve the elderly must keep the best interests of the patient in mind when dispensing pharmaceuticals and not base the decision on the improper influence of drug companies.

Doctors, too, should rely on their best medical judgments and engage in an especially careful analysis when prescribing drugs for off-label use.

Government must combat illegal off-label promotion of these powerful and potentially lethal drugs and uphold nursing home safety standards.

And drug companies should follow the laws, and refrain from promoting drugs for unapproved uses — or paying kickbacks to influence doctors and institutions. About 46 million people are enrolled in Medicare. That will only grow as the huge baby boomer population retires. We cannot afford to leave unaddressed the urgent problem of antipsychotic drug use among elderly nursing home residents.

The opinions in this commentary are solely those of Daniel Levinson.

Read article here:  http://www.cnn.com/2011/OPINION/05/31/levinson.nursing.home.drugs/

« Return to news items


Share

Billion Dollar Drug Company Law Firm Restructures Connecticut Welfare System

Thursday, March 10th, 2011

By Bob Fiddaman and Shelia Matthews
March 10, 2011

For some time now, Sheila Matthews has been suspicious about her home state of Connecticut’s treatment of its most vulnerable children. As a mother of two children and co-founder of Ablechild, her instincts led her to scrutinize the dubious relationships among Connecticut’s Department of Children and Family Services [DCF], the pharmaceutical industry and a billion dollar law firm who has defended the likes of Pfizer Inc and Merck & Co., among others.

Sheila’s investigation has led her on a journey that links a non-profit children’s advocacy group, with assets over $15 million [2009] with nationally-renowned mass tort and class action defense law firms, to the Connecticut DCF – an $865 million bureaucracy, as described by the Connecticut Mirror.

The Connecticut DCF serves approximately 36,000 children and 16,000 families across its four Mandate Areas:

1. Child welfare;
2. Children’s behavioral health;
3. Juvenile Services; and
4. Prevention.

Sheila’s Ablechild has been questioning the Connecticut DCF since 2003, when Ablechild demanded that the Connecticut DCF immediately ban the use of the antidepressant Paxil in its treatment of mental disorders after multiple studies confirmed Paxil increased the risk of suicide in children and adolescents. This was more than a year prior to America’s Food & Drug Association (FDA) announcement that all antidepressants, including Paxil, should bear a black box warning regarding this suicide risk. Ablechild was disturbed that children in state custody were being prescribed this dangerous psychotropic medication. Ablechild’s public pressure paid off, and the Connecticut DCF deemed Paxil unsafe for children and adolescents, and according to the DCF drug approval list, Paxil has not been approved for use in over eight (8) years.

In August 2003, less than one month later, Ablechild reported that the commissioner of the Connecticut DCF held a ‘behind closed doors‘ meeting with Glaxo officials. This meeting was reported by the Associated Press, who wrote:

The maker of the anti-depressant Paxil plans to meet this week with Connecticut officials, weeks after the State stopped using the drug to treat young people in its care.

GlaxoSmithKline, a British pharmaceutical company, is sending its regional medical director and a medical team to meet with officials from the Department of Children and Families. [Source]

Despite repeated requests from Ablechild, the Connecticut DCF refused to inform the public what was discussed at this secret meeting.

Eight years later, Sheila and Ablechild continue to raise concerns and investigate potential wrongdoings and conflicts within the Connecticut DCF. Last month, in February 2011, Sheila attended a meeting sponsored by the Connecticut Behavioral Health Partnership [CBHP], where its medical director, Dr Steven Kant, presented the Husky Behavioral Pharmacy Data. The CBHP is a state vendor that provides mental health services to DCF children. These services are paid, in part, by the State-run insurance program, HUSKY. Incredibly the pharmacy data presentation showed that dangerous psychotropic drugs, like Paxil, are still being prescribed to thousands of children and adolescents. In fact, the Pharmacy Data presentation showed that the HUSKY program, financed by taxpayer dollars, paid drug companies over $60 million for psychotropic drugs for Connecticut’s children and adolescents in 2009 alone – many of which are not approved by the FDA for use in the pediatric population and all of which carry the most serious warning possible regarding the risk of suicide.

According to the pharmacy data presentation: [Which can be downloaded as a Powerpoint presentation HERE]

More than 50% of HUSKY Youth Behavioral med utilizers are on stimulants.
Close to 30% of HUSKY Youth Behavioral med utilizers are on antipsychotics.

The pharmacy data also revealed the following:

Most Frequently Used Behavioral Meds for DCF-Involved Youth

Medications for ADHD

Ritalin (10%)
Adderall (5%)
Vyvanse (4%)
Strattera (3%)

Atypical Antipsychotics

Abilify (11%)
Risperdol (10%)
Seroquel (8%)

Anti-anxiety

Hydroxyzine (2.5%)

Antidepressants

Prozac (4.5%)
Zoloft (4%)
Zyban (3%)
Desyrel (2.5%)
Celexa (2%)

Mood Stabilizers

Lithum (3%)
Depakote (3%)
Lamictal (2.5%)

Curiously, none of the above medications are on the Connecticut DCF list of approved/unapproved drugs listed in its DCF PMAC document.

With this in mind, Sheila Matthews contacted Dr Steven Kant and inquired as to whether any of the above drugs were approved by the Connecticut DCF for use in children.

Dr Kant replied:

… the answer to your question is not that straight forward.. . . Medications may be indicated by age and/or by specific treatment needs so it is not either a simply “yes” or “no”. Also, some medications may have the age indication but for a totally different condition, such as anti epileptic condition. . .Also FDA indications are static, they do not change over time though medical practice is constantly evolving…

Contradicting the very document that lists Connecticut’s approved and unapproved drugs, a “check-off” list that verifies the status of medications, Dr Kant replied, “I don’t think a “check off” for each medication would work in terms of verifying their status.”

With such an ambiguous response from Dr. Kant, we found the DCF Approved Medication List on the Internet. This particular version was revised in 2009.

It appears that the DCF has approved drugs in children that have not been approved for children by the FDA. In fact, the FDA has issued multiple advisories and alerts since 2004 about the increased risk of suicide in children, adolescents and young adults up to age 25 who are treated with psychotropic medications.

And while Fluoxetine (Prozac) is the only medication approved by the FDA for use in treating depression in children ages 8 and older, it still carries a black box warning regarding the risk of suicide.

In contrast, the DCF seems to be ignoring the conclusions of the FDA. Its list of approved medication in children and adolescents include every single antidepressant except paroxetine [Paxil] and venlafaxine [Effexor].

Forest Lab’s citalopram [Celexa] – APPROVED

Forest Lab’s escitalopram [Lexapro] – APPROVED

Solvay Pharmaceuticals’ fluvoxamine [Luvox] – APPROVED

Pfizer’s sertraline [Zoloft] – APPROVED

GlaxoSmithKline’s bupropion [Wellbutrin -also marketed as an anti-smoking cessation drug under the name of Zyban] – APPROVED [1]

Alarmingly, the DCF has produced a guide entitled, “MEDICATIONS USED FOR BEHAVIORAL & EMOTIONAL DISORDERS – A GUIDE FOR PARENTS, FOSTER PARENTS, FAMILIES, YOUTH, CAREGIVERS, GUARDIANS, AND SOCIAL WORKERS” where it writes, “Most of the side effects from the medications are mild and will lessen or go away after the first few weeks of treatment.” The guide also points out possible side effects of SSRI’s/SNRI’s:

SSRIs and SNRIs:

Headache
Nervousness
Nausea
Insomnia
Weight Loss

One of the most dangerous side effects of these medications, suicidal thoughts/ideation, doesn’t even make the 5 bullet-pointed list. The Guide does, however, add the following: “Watch for worsening of depression and thoughts about suicide.”

The DCF Approved Medication List writes:

“The DCF Approved Medication List is a list of psychotropic medications that has been carefully established by the Psychotropic Medication Advisory Committee, a group of DCF and community professionals.”

Sheila has since investigated other advocacy groups that were concerned about the off-label prescribing of psychiatric medications to youths in state custody. This is where she stumbled upon Children’s Rights, a non-profit charity based in New York City.

In 2005, Children’s Rights employed ten (10) attorneys and a staff of 31. It claims to use its expertise to change child welfare red tape and scrutinize failing systems. If the child welfare system fails to respond, Children’s Rights files a lawsuit. If successful, it enforces reform and then monitors its implementation.

In 1989, Children’s Rights had in fact filed a suit against William O’Neill and the Connecticut state Department of Children and Youth Services [DCYS].

The suit charged that an overworked and underfunded DCYS failed to provide services including abuse and neglect investigations, adoption, foster care, mental health care, caseloads and staffing. The case has been pending for over twenty (20) years, and while there have been numerous arguments that DCYS should be more inclusive or has failed to provide certain services, the issue of massive off-label prescription of psychotropic medications has never been brought to the court’s attention.

Children’s Rights is chaired by Alan C Myers, a partner at Skadden, Arps, Slate, Meagher and Flom, a billion dollar law firm which represents the pharmaceutical industry in mass torts and class actions. Myers is also co-head of the firm’s REIT Group [Real Estate Investment Trust].

Also, listed on the Children’s Rights website are individuals and law firms that have served as co-counsel on Children’s Rights’ legal campaigns to reform America’s failing child welfare systems, including:

Missouri - Shook Hardy & Bacon – Eli Lilly Co. and Forest Labs, defended the original Wesbeker Prozac trial in Kentucky and still defend Prozac, Celexa and Lexapro.

New JerseyDrinker Biddle & Reath – GlaxoSmithKline attorneys – defended Paxil as local counsel in Philadelphia cases.

OklahomaKaye Scholer LLP – provides work in Pharmaceutical Products Liability defense and employs an attorney who was former General Counsel of Pfizer, Inc.

A particular success for Skadden Arps occurred in 2010 when it secured a summary judgement ruling for Pfizer Inc. in a suit filed by two insurance companies who sought $200 million in damages for Pfizer’s predecessors alleged “off-label” marketing of its epilepsy drug, Neurontin.

Furthermore, in February 2011, Skadden Arps secured the dismissal of over 200 cases in a multi-district litigation pending against their client, Pfizer Inc. The plaintiffs had alleged injuries related to the use of Pfizer’s anti-epilepsy drug, Neurontin.

Neurontin, the generic version is called gabapentin, is prescribed by psychiatrists for a variety of “off-label” indications. It is often tried as an alternative treatment, when patients are unable to tolerate the side effect of more proven mood stabilizers such as lithium. [2]

Gabapentin has also been associated with an increased risk of suicidal acts or violent deaths.

This is a drug that has been known to cause behavioral problems, which include unstable emotions, hostility, aggression, hyperactivity or lack of concentration.

Children dependent on child welfare systems have rights and, according to its web page, Children’s Rights is dedicated to protecting them.

It should come as no surprise that the site fails to discuss the off-label prescription of non-approved psychotropic medications to children and adolescents, unless this falls under the ‘abuse and neglect’ category?

If Children’s Rights’ motive was to accomplish fixing the child welfare system then why hasn’t it investigated why thousands of children under state care are prescribed “off-label” psychiatric drugs? With a partner in a billion dollar pro-pharmaceutical law firm as its Chair, and supporters who also defend pharmaceutical products, is it safe to assume that its stance on the drugging of children is one that is being ignored?

Children’s Rights push to remove abused and neglected children into safety.

The basic question always comes down to trust. When power, money and a good cause is mixed, it is imperative to check motives. We would be less of a society if we didn’t check out all the facts. Abuse and neglect exist, always has and always will, but society is obligated to ensure those victims are not transformed into “good cause victims” and expensed out. There is no doubt we have a right to question the system and those who claim to promote change for the good of the children within it.

Children’s Rights Chairman, Alan C. Myers, Medical Director of Connecticut Behavioral Health Partnership, Steven Kant and the Connecticut Department of Children and Families may get their knickers in a twist with regard to an advocate of Ablechild and a blogger from Birmingham, UK questioning their motives but hey, what’s the downside of shinning a light on all these players, be they good or bad players?

Sheila’s concern is that Children’s Rights with its multi-million dollar budget and with the help of its billion dollar law firms, will continue to ignore the risks of these unapproved and dangerous medications, under the guise of helping our nation’s most vulnerable children. The question remains: how can the lawyers who defend psychotropic drugs also be the same lawyers who advocate for abused and neglected children to get into state welfare programs which place these children on the same drugs? The conflict is clear and obvious – and it poses an unmistakable danger to children who truly need our help.

[1] Bupropion [also known as Wellbutrin, Zyban] is a non-tricyclic antidepressant.
[2] Gabapentin

Bob Fiddaman is the author of the Seroxat Sufferers blog and the book, “The evidence, however, is clear… the Seroxat scandal.” Chipmunka Publishing.

Sheila Matthews is the co-founder of Ablechild and a mother of two children.

RETURN TO BLOGS PAGE


Share

New Study Links ADHD Drugs, Antidepressants, Hypnotics & Anti-Smoking Drug to 1,527 Acts of Violence

Thursday, December 16th, 2010

Pharmalot, December 16, 2010

by Ed Silverman

For years, there were contentious debates about links between certain prescription meds, notably antidepressants, and suicidal behavior. Now, the focus is turning to violent behavior directed toward others. And a new study is linking 31 widely prescribed drugs – most notably, the Chantix anti-smoking pill – with 1,527 serious acts of violence, such as physical abuse, physical assault and homicide.

The study, which was published in PLoS One, identified 484 drugs that accounted for 780,169 serious adverse event reports of all kinds, including 1,937 cases meeting the violence criteria determined by the researchers. There were 387 reports of homicide, 404 physical assaults, 27 cases indicating physical abuse, 896 homicidal ideation reports and 223 cases described as violence-related symptoms.

Besides Pfizer’s Chantix, 11 antidepressants, three ADHD meds and five hypnotics or sedatives were linked to 79 percent of the violence cases. Looked at another way, no cases of violence were reported for 324 of the 484 drugs evaluated. And so an association with violence appeared “highly unlikely” for nearly 85 percent of all evaluated drugs in widespread clinical use.

This is not, by the way, the first time that Chantix has been linked to violent behavior. The same authors published a study last summer in The Annals of Pharmacotherapy that found Chantix is not only associated with violent and aggressive thoughts and acts, but they also identified some of the common characteristics among people using the pill and their subsequent behavior (see this).

“Acts of violence towards others are a genuine and serious adverse drug event associated with a relatively small group of drugs. (Chantix), which increases the availability of dopamine, and antidepressants with serotonergic effects were the most strongly and consistently implicated drugs,” the researchers write. Interestingly, this finding appears just after the infamous Zoloft defense case drew to a close. That involved a 12-year-old boy who killed his grandparents and his lawyers blamed the antidepressant (read here).

The authors do, however, cite some limitations. The submission of an individual adverse event report does not itself establish causality,” the note, “only that a reporting individual suspected a relationship existed.” And they add that the quality and detail in each report varies. On the other hand, they also say that, “given that violent thoughts or actions are not typically attributed to drug therapy or recorded in medical records, the reporting rate for violence cases could be very low. The selected violence cases do not provide a reliable estimate of how often they might occur.”

In the end, they recommend prospective studies to “establish the incidence, confirm differences among drugs and identify additional common features.”

http://www.pharmalot.com/2010/12/chantix-prescription-drugs-and-violent-acts/

Note from CCHR:  As far back as 1991, the FDA held hearings into antidepressants causing suicidal ideation and violence, largely prompted by CCHR’s demands for an investigation. CCHR testified along with dozens of victims and medical experts.   The FDA panel, largely Pharma funded, refused to issue warnings despite the evidence presented. It would take the FDA another 13 years to finally admit antidepressants cause suicidal ideation and issue black  box warnings on the drugs.  The FDA has still never fully investigated the overwhelming evidence linking antidepressants and other psychiatric drugs to acts of violence and homicide.

Watch this video, produced by CCHR, of the 1991 FDA hearings into antidepressants causing suicide and violence http://www.youtube.com/cchrint#p/c/B9EA75455D155D89/6/FxJomeak4V4

Also Watch This Fox National News Special Report’s from Douglas Kennedy Deadly Drugs - http://www.youtube.com/watch?v=9S-7aNPf33A

« Return to news items


Share

Psychiatrist on Payroll of Glaxo Pleads Guilty to Research Fraud

Monday, November 29th, 2010

NaturalNews, November 29,2010

by David Gutierrez

GlaxoSmithKline, manufacturer of Paxil, paid Palazzo $5,000 for every child she enrolled in the study.

A psychiatrist on the payroll of GlaxoSmithKline has been sentenced to 13 months in prison after pleading guilty to committing research fraud in trials of the company’s antidepressant Paxil on children.

Maria Carmen Palazzo is already serving a sentence of 87 months for defrauding Medicare and Medicaid.

Palazzo was accused by the FDA of enrolling children in a clinical trial even though she knew they did not actually suffer from major depressive or obsessive compulsive disorder, the conditions being studied. Palazzo then falsified records and psychiatric diagnoses.

GlaxoSmithKline, manufacturer of Paxil, paid Palazzo $5,000 for every child she enrolled in the study.

The case’s significance goes beyond simple research fraud, as Glaxo is now defending itself against charges that for 15 years it deliberately concealed evidence that Paxil increases the risk of suicide in children.

Glaxo is also defending itself against accusations that it manipulated data to conceal the risks of its diabetes blockbuster Avandia, and that it failed to warn parents that Paxil may cause birth defects if taken by pregnant women. The company has already agreed to pay more than $1 billion to settle roughly 700 birth defect lawsuits; another 100 or so suits are pending.

Although the FDA eventually required Paxil to carry a warning about the risk of birth defects and an even more prominent “black box” warning about suicide risk, many critics allege that the agency acted too slowly.

“There [had] been hints for many years that antidepressants, such as Paxil, when given to children, can cause serious side effects, including suicide, but the FDA delayed taking any action to prevent these drugs from being prescribed for children,” writes Brent Hoadley in Too Profitable to Cure.

Palazzo will not actually serve any additional prison time for potentially placing children’s safety at risk; her new term will be served concurrently with her first.

http://www.naturalnews.com/030557_psychiatry_fraud.html

« Return to news items


Share

Are Soldiers Suicides Caused by Prescription Drugs?—At Fort Brag 4,994 troops on antidepressants/664 on antipsychotics

Friday, October 15th, 2010

http://www.opednews.com/images/oenearthlogo.gif

by Martha Rosenberg

The suicide rate among troops is astonishing.

In 2009 there were 160 active duty suicides, 239 suicides within the total Army including the Reserves, 146 active duty deaths from drug overdoses and high risk behavior and 1,713 suicide attempts, says the Army’s suicide report, released in July.

Not only are more troops dying from their own hand than combat says the Army report, titled Health Promotion, Risk Reduction, Suicide Prevention, 36 percent of the suicides were troops who were never deployed.

Also astonishing is the psychoactive drug rate among active duty-aged troops, 18 to 34, which is up 85 percent since 2003 according to the military health plan, Tricare. Since 2001, 73,103 prescriptions for Zoloft have been dispensed, 38,199 for Prozac, 17,830 for Paxil and 12,047 for Cymbalta says Tricare 2009 data, which includes family prescriptions. All of the drugs carry a suicide warning label.

In addition to the leap in SSRI antidepressants, prescriptions for the anticonvulsants Topamax and Neurontin rose 56 percent in the same group since 2005 says Navy Times, drugs which the FDA warned last year double suicidal thinking in patients.

In fact 4,994 troops at Fort Bragg are on antidepressants right now says the Fayetteville Observer. Six hundred and sixty-four are on an antipsychotics and “many soldiers take more than one type of medication.”

Troops may also be taking Chantix, an antismoking drug so linked to violence and self-harm Secretary of the VA, James Peake was forced to defend its use before the House Committee on Veterans’ Affairs in 2008 even in drug trials . “If you know the drug induces suicidal thoughts,” an unappeased Committee chair Bob Filner D-Ca. asked Rep. Filner,” Why don’t you just stop?”

Even widely prescribed asthma drugs like Singulair and Advair are linked to suicide says the FDA and have been cited in young people’s deaths.

And who knows what happens when the drugs are mixed with mood stabilizers, insomnia and pain pills and antianxiety and antipsychotic pills, combinations which have never been tested for safety?

Links between suicide and even murder-suicide and SSRI and SNRI antidepressants have been long recognized.

Traci Johnson, a healthy 19-year-old with no mental problems, hung herself during Lilly trials of Cymbalta in the drugmaker’s own clinic in 2004. Columbine shooter Eric Harris had reportedly just switched from Zoloft to Luvox. Red Lake shooter Jeff Weise who killed 10 on a Minnesota Indian reservation in 2005 had just upped his Prozac. And the Virginia Tech shooter, Cho Seung-Hui, was also on psychoactive medications say news reports.

Yet even though Amercians have doubled their antidepressants since 1999 so that 10 percent of the population or 27 million now take them suicides have climbed by five percent since 1999 and 16 percent in middle aged adults says an article in the American Journal of Preventive Medicine in 2008.

In fact, the high percentage of civilian suicides on psychoactive drugs is probably the clearest indication that military life is not the only cause of the shocking troop suicides: In September alone, there were 18 civilian suicides, 11 murders, 2 murder suicides and other violence linked to people who were using or had used antidepressants, according to published reports. http://www.ssristories.com/index.php?sort=what&p=recent

A 54-year-old respiratory patient with a breathing tube and an oxygen tank and no previous criminal record held up a bank in Mobile. She had gone off her antidepressants.

An enraged man in Australia, also off his antidepressants, chased his mailman and threatened to cut his throat…for bringing him junk mail.

And a 58-year-old Amarillo man with no criminal history tried to abduct three people, killing an Oklahoma grandmother in the process. He had “an antidepressant in his blood,” said police.

Also in the thirty day period, a 60-year-old grandmother in Seattle killed three family members and herself; a disc jockey in Bristol, UK set himself on fire; and a man in Exeter, UK man was determined to have stabbed himself in the heart. All were on antidepressants.

Finally, in the month of September, legal proceedings began against two mothers and a father charged with killing their own children.

Over 4,000 published reports of violent and bizarre behavior of people affected by antidepressants on the web archive ssristories.com reveal the same out of character violence and self harm in civilians, currently seen in the military.

Twenty people set themselves on fire. Ten bit their victims (including a biter who was sleepwalking and a woman, on Prozac, who bit her 87-year-old mother into critical condition.) Three men in the 70s and 80s attack their wives with hammers. Many stab their victims obsessively — one even stabs furniture after killing his wife — and 14 parents drown their children, a crime seldom heard of before the 2001 Andrea Yates case. Yates drowned her five children on the antidepressant Effexor which manufacturer Wyeth (now Pfizer) “issued no public warning” about says the Associated Press.

Then there’s the North Carolina pilot on Zoloft who sings, “I’m going down for the last time,” into the cockpit voice recorder before he crashes his plane in June. And the Mayor of Coppell, Texas, Jayne Peters who kills herself and her daughter in July over the grief of losing her husband. Police find antidepressants at the home.

Such murder-suicides committed by women used to be rare says Betty Henderson the web site’s moderator and researcher. “Before the SSRI antidepressants, women committed five percent of the murder-suicides and now they account for almost 15 percent of this type of violence,” she said in an AlterNet interview.

Antidepressants are also causing women to become neo sexual predators says Henderson. “There have been more than a dozen recent cases of women school teachers molesting their young students under the influence or withdrawal of antidepressants. Who heard of this type of sexual aberration before the antidepressant craze?”

Why don’t doctors and media outlets publicize the names of these volatile drugs?

It’s a good questions said Dr. Gary Kohls, a Minnesota family practitioner, in an oped written after Iraq veteran Matthew Magdzas killed his pregnant wife, their 13-month-old daughter, their dogs and himself in Wisconsin in August.

“Nobody in the media has, to my knowledge, had the courage to report what the drugs were, nor have they interviewed the physician or his clinic to find out the rationale for prescribing drugs that have common violence-inducing effects (with black box warnings stating that in the prescribing information),” he writes. “Therefore nothing has been learned from this important teachable moment, probably because revealing the common reality of prescription drug-induced violence would be economically harmful for the sacred cows of Big Pharma and Big Medicine.”

Still, Sen. Jim Webb, D-Va. called the one of every six troops who are now on psychoactive drugs “pretty astounding and also very troubling,” in Senate hearings this year and Retired Col. Bart Billings, a former Army psychologist who has also testified before Congress, says, “I feel flat out that psychiatrists are directly responsible for deaths in our military, for some of these suicides,” in a March Marine Times article. “I think it’s criminal, what they are doing.”

Even Katie Bagosy, the wife of Marine Sgt. Tom Bagosy who took his own life in May indicts the Neurontin medication he was prescribed for his downfall.

“He told me, ‘It all started to get worse when I got on this medication.’ Looking back, that was the beginning of the end,” she says in an article called A Prescription For Tragedy in the current National Journal.

http://www.opednews.com/articles/1/Are-Soldiers-Suicides-Caus-by-Martha-Rosenberg-101015-973.html

« Return to news items


Share

Glaxo Still Haunted by Faked Paxil Studies in Kids; Crooked psychiatrist expected to plead guilty to criminal charges today

Thursday, August 19th, 2010

“The use of Paxil in children became extremely controversial after it emerged that GSK knew for 15 years, but didn’t tell anyone until 2006, that the drug may carry a risk for suicide. The drug now carries a black-box warning for suicide risk in children.”

BNET
By Jim Edwards
August 19, 2010

A crooked doctor who faked data in a GlaxoSmithKline (GSK) study of the antidepressant Paxil in children pled guilty to criminal charges today, causing groans among GSK’s senior management as the company hopes to fend off a different criminal investigation into whether it manipulated clinical data on its diabetes drug, Avandia. She was sentenced to 13 months in prison.

The two cases are technically completely separate, but they’re both about data manipulation. GSK has been accused of sitting on data showing risks on both drugs; and the FDA previously shut down one of GSK’s factories where both drugs were made.

Thus, the expected guilty plea of Dr. Maria Carmen Palazzo today is a reminder to managers everywhere that cutting ethical corners can cause unwanted chickens to return to their roosts, even years later.

Palazzo was indicted in 2007 on 40 counts of defrauding Medicare and Medicaid at her New Orleans clinic, and 15 counts of conducting fraudulent clinical trials. The charges followed an FDA accusation that she had enrolled 26 children in studies of Paxil for obsessive-compulsive disorder and major depressive disorder. She included children in the trial — which was given the cutesey nickname “Kiddie-Sads-Present and Lifetime” — who did not have the diagnoses being studied. GSK gave her more than $5,000 for each child she enrolled.

At trial, Palazzo was convicted on 39 counts of healthcare fraud and was sentenced to 87 months in prison and forfeiture of $655,000. The clinical trial fraud charges were thrown out, but prosecutors appealed and won a ruling this year reinstating those charges. That appears to be the reason Palazzo is reappearing in court to make a plea.

The use of Paxil in children became extremely controversial after it emerged that GSK knew for 15 years, but didn’t tell anyone until 2006, that the drug may carry a risk for suicide. The drug now carries a black-box warning for suicide risk in children.

Read entire article here:  http://www.bnet.com/blog/drug-business/10-years-later-glaxo-still-haunted-by-faked-studies-of-paxil-in-kids/5545

Read more about Palazzo here:
http://medicaresmostwanted.blogspot.com/2007/06/dr-maria-carmen-palazzo-has-been.html

« Return to news items


Share

Behind the Psychopharmaceutical Industrial Complex; Pharma-funded front groups masquerading as “patient advocates”

Tuesday, June 22nd, 2010

Scoop Independent News
By Evelyn Pringle
June 22, 2010

Non-Profit Advocacy Groups

As a main component of the Psychopharmaceutical Industrial Complex, the so-called “patient advocacy” organizations have become the leading force behind the American epidemic of mental illness over the past two decades.

Drug makers, and their foundations, funnel millions of dollars to these non-profits every year. In return, the leaders recruit their members as foot soldiers to carry out the latest marketing campaigns and to provide a fire-wall so that no money trail can be tracked back to the drug companies.

Gigantic Pyramid

The psychiatric front groups form a gigantic pyramid and once pharmaceutical money enters the system through a major organization, it gets channeled into a huge spider-web that weaves through many groups, making it nearly impossible to keep track of where it came from or where it all went. Often, when the grant reports of the drug companies list a large donation to one organization, the annual reports of the other groups will show smaller gifts from that same organization.

The “charity” groups are exempt from income tax and the “contributions” funneled through them are tax deductible. The money is used for disease mongering campaigns to both market disorders and pressure public health care programs and private insurers to pay for expensive treatments.

“Presenting themselves as patient advocacy groups is highly disingenuous not only to their membership, many of which may have a sincere desire to help a loved one or a family member with mental problems, but to legislators, the press and the American public — for they have consistently lobbied for legislation that benefits the mental health and pharmaceutical industries which fund them, and not patients they claim to represent,” according to Citizens Commission on Human Rights International, a mental health watchdog group.

In a June 2, 2010, commentary titled, “Psychiatric Fads and Overdiagnosis,” on the Psychology Today website, Dr Allen Frances points out that it “is too bad that there is no advocacy group for normality that could effectively push back against all the forces aligned to expand the reach of mental disorders.”

The leaders of the supposedly “non-profits” earn outrageously high salaries, along with excellent benefit packages, while many of the patients they claim to represent are encouraged to seek federal disability payments of under $700 a month, and apply for public housing, food stamps, and Medicaid, to make ends meet. The top officials will often move from a leadership role in one organization to a higher position in another.

The drug makers rely on the front groups to do their bidding any time profits are threatened. For instance, if the FDA is considering adding a black box warning about a deadly side effect to a drug’s label, which may result in a drop in sales, representatives of front groups will show up at the FDA advisory panel hearings to testify against adding the warning.

They will also lobby FDA panels whenever there is a chance to increase profits, such as enlarging the drug customer base. In June 2009, the Psychopharmacologic Drugs Advisory Committee was set to meet to evaluate AstraZeneca’s Seroquel, Pfizer’s Geodon and Eli Lilly’s Zyprexa for use with 13 to 17 year-olds diagnosed with schizophrenia, and 10 to 17 year-olds diagnosed with pediatric bipolar disorder.

On June 8, 2009, nine front groups issued a joint statement urging the panel to vote to approve all three drugs for kids. The groups signing the letter included the American Academy of Child and Adolescent Psychiatry, American Foundation for Suicide Prevention, American Psychiatric Association, Child and Adolescent Bipolar Foundation, Children and Adults with Attention-Deficit/Hyperactivity Disorder, Families for Depression Awareness, Mental Health America, National Alliance on Mental Illness, and the National Council for Community Behavioral Healthcare.

Read entire article:  http://www.scoop.co.nz/stories/HL1006/S00162.htm

Also see:  http://www.cchrint.org/psycho-pharmaceutical-front-groups/

« Return to news items


Share

Wrongful Death Suit Claims Anti-depressant Led to Elderly Couple’s Murder-Suicide

Friday, May 28th, 2010

The West Virginia Record
By Lawrence Smith
May 28, 2010

RIPLEY — The murder-suicide of a Jackson County couple is at the center of a wrongful death, and product liability suit against New York pharmaceutical company.

Forest Laboratories and Forest Pharmaceuticals are named as co-defendants in a lawsuit filed in Jackson Circuit Court on April 30 by Robin J. Hall. In her six-count complaint, Hall, 49, a resident of Staats Mill, alleges Forest failed to alert both her father, and his physician of potentially dangerous side-effects of medication he was taking which resulted in him taking the life of his wife, then his own.

Located in New York, N.Y., Forest Laboratories is the parent company of Forest Pharmaceuticals based in St. Louis, Mo. Forest Pharmaceuticals handles the manufacture, sell and distribution of all Forest products in the United States.

In her suit, Hall says her father, Robert Raines, was prescribed Celexa by his doctor on April 24, 2008. Later that day, Raines purchased Celexa in 20 mg tablets.

Celexa is the brand name for Citalopram, a psychoactive drug in the class of selective serotonin reuptake inhibitors. It is used mostly for treatment of depression by altering a person’s serotonin levels.

Forest, Hall alleges, was aware Celexa caused an increased risk of suicidal behavior in people over 65, yet failed to conduct any further testing or investigation. Also, she alleges in its promotional materials, Forest failed to warn not only patients, but also physicians and pharmacists of that risk.

As early as Oct. 15, 2004, Forest was aware of the causality between SSRI drugs like Celexa and suicidal behavior in children. It was then, the U.S. Food and Drug Administration ordered Forest to put a “black box warning” on Celexa for anyone under the age of 24 about the potential risk of suicidal behavior.

Read entire:  http://www.wvrecord.com/news/227152-anti-depressant-led-to-elderly-couples-murder-suicide-jackson-suit-claims

« Return to news items


Share

The Huffington Post: “Pilots Taking Antidepressants? The FAA Is Risking Our Lives”

Monday, April 19th, 2010

The Huffington Post
By Peter Breggin
April 19, 2010

A few years ago I was hired by the FAA to defend the agency against a suit brought by a pilot who wanted to fly while taking a prescription antidepressant. I helped the FAA formulate its defense of the agency’s ban on pilots using antidepressants and, as a result, the ban remained in effect. Pilots remained unable to fly while taking antidepressants, including the newer ones such as Prozac, Paxil, Zoloft, Celexa, Lexapro and Effexor.

How times have changed. Ignoring the scientific data on adverse drug effects that the agency and I generated and evaluated for the earlier case, the FAA is lifting its 70-year-old ban on allowing pilots to take antidepressants. Has the science changed–improving the adverse reaction profile of these drugs? To the contrary, since that time my most dire observations have been confirmed in the FDA-approved label for all antidepressants. Now there is not only a Black Box Warning for suicidality in children, youth and young adults, but also a lengthy Warnings section about a variety of extremely dangerous abnormal behavioral reactions in all ages including aggression, hostility, disinhibition, impulsivity and mania. Even when not severe, these reactions impair judgment and increase the likelihood of accidents and violence.

According to the FDA-approved guidelines, prescribers are supposed to give a special Medication Guide to patients and their families that warns about dangerous drug-induced reactions including suicide, violence and a variety of unexpected negative behaviors. Originally intended for children and youth, the Medication Guide is now expanded to cover all age groups, including adults. The Medication Guide for all ages can be found at the conclusion of each FDA-approved label for antidepressant drugs in the 2010 Physicians’ Desk Reference.

Why did the FAA lift the ban on pilots using antidepressants? According to FAA statements to the media, depressed pilots sometimes kept on flying while secretly taking antidepressants. “Our concern is that they haven’t necessarily been candid,” FAA Administrator Randy Babbitt reportedly told the press on a conference call. They were flying below the radar of drug testing, so to speak. The new policy not only allows pilots to use antidepressants, it grants a degree of amnesty to those who have been using them illegally in the past.

The FAA feels it’s safer to allow the use of antidepressants because it will make it easier for pilots to obtain needed treatment for depression. It supposedly will also make it easier to monitor their use of these dangerous drugs. If we accept this argument, why not legalize stimulants such as amphetamine as well? They would help keep the overworked pilots awake. And while the FAA is at it, why not let them use marijuana, since they may be doing it illegally on their own without anyone monitoring them.

Unfortunately, monitoring pilots on antidepressants won’t work nearly as well as might be hoped. Many severe emotional and behavioral reactions occur in the first one to three days of antidepressant dosing, or shortly after dose changes, either up or down–long before the next scheduled appointment. Although close monitoring and informing the family to be on the alert can be helpful, and should be done, it won’t prevent many of the drug reactions that occur abruptly and without warning. In addition, doctors too often fail to warn the patient and the family about the risks. As a medical expert, I’ve learned how cavalier some prescribers are in regard to warning patients about the adverse effects of any psychiatric drugs.

Read entire article:  http://www.huffingtonpost.com/dr-peter-breggin/antidepressants-pilots-ta_b_542240.html

« Return to news items


Share